Page contents Key factsDecisionKey facts Invented name Hexvix Active Substance hexaminolevulinate Therapeutic area Oncology Decision number P/0070/2013 PIP number EMEA-001245-PIP01-11 Pharmaceutical form(s) Vaginal ointmentpowder and solvent for intravesical solution Condition(s) / indication(s) Diagnosis of bladder cancerTreatment of cervical dysplasia Route(s) of administration Vaginal useIntravesical use Contact for public enquiries Photocure ASAE-mail: info@photocure.noCountry: NorwayTel. + 47 22062216Fax + 47 22062218 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 26/03/2013DecisionP/0070/2013: EMA decision of 26 March 2013 on the granting of a product-specific waiver for hexaminolevulinate (Hexvix), (EMEA-001245-PIP01-11)AdoptedReference Number: EMA/114799/2013 English (EN) (83.29 KB - PDF)First published: 30/04/2013Last updated: 30/04/2013ViewShare this page